Stock Taper
SCREENER COMPARE ANY 2 STOCKS
AURA
AURA BIOSCIENCES, INC.
NASDAQ
$7.40
▼ DOWN 3.90% (-0.30)

KEY STATISTICS

Market Cap$765.43 M
52w High$9.54
52w Low$4.73
Dividend Yield—
Frequency—
P/E-4.25
Volume441.40K
Shares Out.103.44M

COMPANY

LEADERSHIP

Natalie C. Holles
CHIEF EXECUTIVE
Natalie C. Holles

COMPENSATION 2026

Salary$431,816
Stock Awards$1,040,998
Incentive Plan Pay$157,462
All Other Comp.$16,803
Total$6,816,256

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 29, 2021
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
113

PRICE TARGET

Target High$18.00
Target Low$17.00
Target Median$17.50
Target Consensus$17.50

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

PRICE

$7.40 ▼ DOWN 3.90% (−$0.30)
$7.35$7.50$7.65$7.809:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM7.40

About Aura Biosciences, Inc.

https://www.aurabiosciences.com ↗

Aura Biosciences, Inc. is a Cambridge-based biotech company developing virus-like drug conjugates for cancer, including AU-011 for ocular and urologic tumors with high unmet needs.

INDUSTRY

Biotechnology

A PRODUCT AURA BIOSCIENCES, INC. IS KNOWN FOR

Belzupacap Sarotalocan (bel-sar; AU-011)
Belzupacap Sarotalocan (bel-sar; AU-011)

Belzupacap sarotalocan is a first-in-class virus-like drug conjugate in Phase 3 trials for early-stage choroidal melanoma, aiming to be the first vision-preserving targeted therapy for this rare, life-threatening eye cancer.

COMPETITORS

COMPETITOR
EYPT COMPARE
IDYA COMPARE
IMCR COMPARE
KOD COMPARE
OCUL COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
81
LISTED HERE
13
RANKED BY POSITION SIZE
VTS.AX
0.00% · 3.0M
XSU.TO
0.01% · 1.2M
SCHC
0.03% · 339.6K
FESM
0.04% · 314.6K
DFAS
0.01% · 174.8K
ZPRR.DE
0.01% · 110.8K
BBC
0.72% · 48.9K
XRSU.L
0.01% · 38.5K
AVSC
0.01% · 29.3K
RSSL
0.01% · 21.3K
PRFZ
0.00% · 15.7K
BIB
0.03% · 3.7K
WCEO
0.17% · 3.0K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
61.10%
HOLDERS
180
TOP 12 OF 180 · RANKED BY POSITION SIZE
Tcg Crossover Management, LLC
9.5M sh · $67.69M
Suvretta Capital Management, LLC
7.2M sh · $51.16M
Frazier Life Sciences Management, L.P.
7.1M sh · $50.41M
Matrix Capital Management Company, LP
6.9M sh · $42.78M
Long Focus Capital Management, LLC
5.1M sh · $36.35M
Adage Capital Partners Gp, L.L.C.
4.9M sh · $32.65M
Blackrock, Inc.
4.7M sh · $33.42M
Caligan Partners LP
4.3M sh · $30.52M
Fcpm Iii Services B.V.
4.1M sh · $28.78M
Orbimed Advisors LLC
3.3M sh · $23.67M
Medicxi Ventures Management (Jersey) Ltd
3.0M sh · $21.58M
Blackrock Inc.
3.0M sh · $22.72M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
Person Julie
— · —
2026-08-12
★
Kratz Erica
— · —
2026-08-10
★
Abu-Absi Susan
— · —
2026-08-10
★
DIRECTOR
Bender Jeremy
Purchase · 60.0K shares
2026-07-07

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS
HC Wainwright & Co. BUY

SECTORS PEERS

PEERPRICE
LBRX$47.73COMPARE
SLDB$9.77COMPARE
DSGN$15.11COMPARE
ANNX$4.97COMPARE
ALT$3.11COMPARE
RCKT$3.86COMPARE
DBVT$13.54COMPARE
QSI$0.78COMPARE